Incyte Corporation (INCY) has an average broker rating of 1.29, which is interpreted as a Strong Buy, as rated by 12 equity analysts. Nonetheless, 9 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 2 other analysts advise a Buy. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.
Incyte Corporation (INCY) : 10 investment research analysts covering Incyte Corporation (INCY) have an average price target of $93.9 for the near short term. The highest target price given by the Brokerage Firm to the stock is $135 and the lowest target is $76 for the short term. Analysts expect the variance to be within $16.31 of the average price.
For the current week, the company shares have a recommendation consensus of Buy.
Incyte Corporation (NASDAQ:INCY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $89.09 and $88.66 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $90.99. The buying momentum continued till the end and the stock did not give up its gains. It closed at $90.81, notching a gain of 2.09% for the day. The total traded volume was 797,156 . The stock had closed at $88.95 on the previous day.
Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f